Under fire for Truvada US pricing at House hearing, Gilead chief O'Day touts R&D costs, asserts governments patents are void
Gilead chief Daniel O’Day spent more than three hours defending the $2000 monthly price of its HIV prevention pill, Truvada, at a US House committee on oversight and reform hearing Thursday, in response to a tsunami of rage from AIDS activists, lawmakers and patients regarding its pricing policy.
Image: Daniel O’Day at the hearing. C-SPAN
Truvada — emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) — was approved in 2004 to treat HIV. In 2012, it was sanctioned by the FDA as a preventative treatment or PrEP (pre-exposure prophylaxis), in which individuals at high risk for HIV take medicines daily to lower their chances of contracting the infection. According to the CDC, daily PrEP reduces the risk of getting HIV via sexual intercourse by more than 90%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.